Autores: Fadila, S.; Beucher, B.; Gonzalez Dopeso-Reyes, I.; Mavashov, A.; Brusel, M.; Anderson, K.; Ismeurt, C.; Goldberg, E. M.;
Ricobaraza Abarquero, Ana;
Hernández Alcoceba, Rubén; Kremer, E. J. (Autor de correspondencia); Rubinstein, M. (Autor de correspondencia)
Resumen:
Dravet syndrome (DS), an intractable childhood epileptic encephalopathy with a high fatality rate, is typically caused by loss-of-function mutations in one allele of SCN1A, which encodes NaV1.1, a 250-kDa voltage-gated sodium channel. In contrast to other epilepsies, pharmaceutical treatment for DS is limited. Here, we demonstrate that viral vector-mediated delivery of a codon-modified SCN1A open reading frame into the brain improves DS comorbidities in juvenile and adolescent DS mice (Scn1aA1783V/WT). Notably, bilateral vector injections into the hippocampus and/or the thalamus of DS mice increased survival, reduced the occurrence of epileptic spikes, provided protection from thermally induced seizures, corrected background electrocorticographic activity and behavioral deficits, and restored hippocampal inhibition. Together, our results provide a proof of concept for the potential of SCN1A delivery as a therapeutic approach for infants and adolescents with DS-associated comorbidities.
